Arctium aglycone derivatives, their preparation methods, and their applications in diabetic nephropathy
By modifying arctigenin through esterification, carbamylation, or etherification, derivatives with improved water solubility and metabolic stability were prepared. This overcame the shortcomings of arctigenin in the treatment of diabetic nephropathy, achieved cell protection and wound healing effects, and is suitable for the preparation of drugs for the prevention and treatment of diabetic nephropathy.
Patent Information
- Application Number
- CN202611130603.2
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2026-07-28
- Publication Date
- 2026-11-17
AI Technical Summary
Arctigenin has drawbacks in clinical applications, including poor water solubility, unstable physiological environment, low oral bioavailability, and high toxicity upon intravenous injection, which limit its efficacy in the treatment of diabetic nephropathy.
A new class of arctigenin derivatives were prepared by esterification, carbamylation, or etherification of the C4-OH of arctigenin, which improved its water solubility and metabolic stability. The reaction was carried out in the presence of specific organic solvents and bases to obtain derivatives with improved drug-like properties.
It improves the water solubility and metabolic stability of arctigenin, exhibits concentration-dependent cell protection, can restore cell vitality, improve adhesion and promote wound healing, and is suitable for the preparation of drugs for the prevention and treatment of diabetic nephropathy.
Smart Images

Figure CN123106587A_ABST
Abstract
Description
Technical Field
[0001] This invention belongs to the field of medicinal chemistry, specifically relating to arctigenin derivatives, their preparation methods, and their application in diabetic nephropathy. Background Technology
[0002] Diabetes mellitus is a metabolic disorder syndrome caused by genetic factors, immune dysfunction, insulin resistance, and other factors, clinically characterized primarily by hyperglycemia. Diabetic kidney disease (DKD) is one of the most common microvascular complications of diabetes and a leading cause of end-stage renal disease. Clinical manifestations include proteinuria, progressive decline in renal function, and eventual renal failure. Current clinical treatment mainly relies on strict control of blood glucose and blood pressure, and the use of renin-angiotensin system blockers. However, these measures can only slow disease progression and cannot prevent patients from reaching end-stage renal disease. Therefore, developing more effective drugs for the treatment of diabetic kidney disease is of significant clinical importance.
[0003] Arctigenin is the main active ingredient of the traditional Chinese medicine burdock seed. Studies have shown that arctigenin possesses various pharmacological activities, including anti-inflammatory, antioxidant, antitumor, hypoglycemic, and hypotensive effects. Recent research has discovered that arctigenin has a significant therapeutic effect on diabetic nephropathy, reducing proteinuria, improving glomerular damage, and protecting podocytes. Therefore, arctigenin and its derivatives have broad application prospects in the preparation of drugs for treating diabetic nephropathy.
[0004] However, arctigenin itself has significant physicochemical defects, including poor water solubility, physiological instability, low oral bioavailability, and high intravenous toxicity, which severely limit its clinical application. To overcome these shortcomings, this invention uses arctigenin as a lead compound for structural modification, aiming to improve its physicochemical properties and bioavailability, thereby finding a more effective active compound for drug development. Summary of the Invention
[0005] To address the shortcomings of existing methods, this invention provides a class of arctigenin derivatives, their preparation methods, and applications. This invention increases the water solubility and metabolic stability of arctigenin derivatives by protecting the hydroxyl groups in arctigenin with different substituents. Furthermore, the corresponding synthetic methods and their applications in diabetic kidney disease were investigated.
[0006] To solve the above-mentioned technical problems, the present invention provides a burdock aglycone derivative having the following structure:
[0007]
[0008] Wherein: P is selected from C1-C8 aliphatic acyl, N-substituted carbamoyl, aromatic heterocyclic carbamoyl, and saturated heterocyclic alkyl acyl. When P is hydrogen, it is abbreviated as ATG.
[0009] Further, in the above technical solution, P is selected from pivaloyl, 3,3-dimethylbutyryl, acetyl, n-hexanoyl, cyclopropylformyl, 4-pentenyl, N,N-diethylcarbamoyl, N-ethyl-N-methylcarbamoyl, N-methylpiperazincarbamoyl, pyridin-4-formyl, 2-chloro-pyridin-4-formyl, morpholinylacetic acid, or 4-methylpiperidinylacetic acid. That is, the arctiin derivative of the present invention is selected from the following specific structures:
[0010]
[0011]
[0012]
[0013]
[0014]
[0015] Furthermore, in the above technical solution, in the most preferred embodiment, P is selected from N-methylpiperazinformyl (corresponding to A-3).
[0016] The present invention also provides a method for preparing the aforementioned arctigenin derivative, comprising the following steps: dissolving arctigenin in an organic solvent, adding the corresponding acyl chloride or alkyl halide, and reacting in the presence of a base; or adding the corresponding carboxylic acid, reacting in the presence of EDCI and DMAP, and obtaining the arctigenin derivative by separation and purification.
[0017] Furthermore, in the above technical solution, the organic solvent is selected from DMSO, DMF, and dichloromethane.
[0018] Furthermore, in the above technical solution, the alkali is selected from triethylamine and potassium carbonate.
[0019] The present invention also provides a pharmaceutical composition for treating diabetic kidney disease, wherein the active ingredient comprises the aforementioned arctigenin derivative or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
[0020] The present invention also provides the application of the aforementioned arctigenin derivative in the preparation of drugs for treating diabetic kidney disease.
[0021] Furthermore, in the above technical solution, the kidney disease is selected from MPC-5, HEK293, and HEK293T cell damage. Attached Figure Description
[0022] Figure 1 The diagram shows the activation activity of a series of derivatives for PP2A.
[0023] Figure 2 The graph shows the proliferation activity of a series of derivatives after 24 hours of treatment with MPC-5, HEK293, and HEK293T cell lines.
[0024] Figure 3 The PP2A activation activity diagram of the preferred compound A-3;
[0025] Figure 4 This is an experimental diagram showing the proliferation activity and cell adhesion of podocytes induced by high glucose after A-3 treatment.
[0026] Beneficial effects of the invention
[0027] A. The derivatives described in this invention are obtained by esterification, carbamylation or etherification of arctigenin C4-OH, which has the advantages of simple synthesis process, readily available raw materials and significantly improved drug properties.
[0028] B. The derivatives described in this invention can effectively improve water solubility and metabolic stability, and exhibit concentration-dependent cytoprotective effects in a high glucose-induced MPC-5 cell injury model, including restoring cell viability, improving adhesion, promoting wound healing and inhibiting excessive migration. They can be used to prepare drugs for the prevention and treatment of diabetic nephropathy. Detailed Implementation
[0029] The following embodiments will further illustrate the present invention, but are not intended to limit the invention.
[0030] Example 1: Synthesis of compound A-1
[0031]
[0032] 100 mg of arctigenin was dissolved in 3 mL of dichloromethane, followed by the addition of 88 μL of N,N-diethylchloroformamide and 300 mg of potassium carbonate. The mixture was heated to 80 °C and reacted for 4 h. The reaction was then monitored by TLC until completion. The reaction solution was extracted with equal volumes of dichloromethane and water, and the organic phase was retained. The solution was dried over anhydrous sodium sulfate, and excess solvent was removed by vacuum distillation. The crude product was then purified by TLC to obtain the pure product. 1H NMR (400 MHz, CDCl3) δ 7.02 (d, J = 8.0 Hz, 1H), 6.82 – 6.74 (m, 2H), 6.70 – 6.65 (m, 1H), 6.56 (dd, J = 8.1, 2.1 Hz, 1H), 6.54 – 6.47 (m,1H), 4.16 (dd, J = 9.1, 7.1 Hz, 1H), 3.95 – 3.90 (m, 1H), 3.87 (s, 3H), 3.85(s, 3H), 3.78 (s, 3H), 3.43 (dd, J = 28.1, 7.1 Hz, 4H), 2.99 (d, J = 5.9 Hz,2H), 2.69 – 2.49 (m, 4H), 1.29 – 1.19 (m, 6H). 13 C NMR (101 MHz, CDCl3) δ178.69, 154.07, 151.84, 148.99, 147.81, 139.58, 135.73, 130.34, 123.21,122.11, 120.56, 113.21, 111.86, 111.38, 71.34, 55.88, 55.80, 46.49, 42.31,42.05, 40.92, 38.18, 34.62, 34.52, 14.03, 13.41.
[0033] Example 2: Synthesis of compound A-2
[0034]
[0035] 100 mg of arctigenin was dissolved in 3 mL of DMF, and 100 mg of N-ethyl-N-methylformyl chloride and 300 mg of potassium carbonate were added. The mixture was stirred at room temperature, and the reaction was monitored by TLC until completion. The reaction solution was extracted with equal volumes of ethyl acetate and water, and the extraction was repeated three times. The organic phase was retained, dried over anhydrous sodium sulfate, and excess solvent was removed by vacuum distillation. The crude product was purified by column chromatography to obtain the pure product. 1H NMR (400 MHz, CDCl3) δ 7.01 (d, J = 8.0 Hz, 1H), 6.82 – 6.74(m, 2H), 6.68 (dd, J = 8.1, 1.9 Hz, 1H), 6.57 (dd, J = 8.1, 2.0 Hz, 1H), 6.52(d, J = 2.0 Hz, 1H), 4.17 (dd, J = 9.1, 7.0 Hz, 1H), 3.95 – 3.90 (m, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 3.79 (s, 3H), 3.46 (dq, J = 33.1, 7.1 Hz, 2H),3.10 (s, 1H), 2.99 (d, J = 5.5 Hz, 3H), 2.76 – 2.67 (m, 1H), 2.67 – 2.48 (m,4H), 1.28 – 1.18 (m, 3H). 13 C NMR (101 MHz, CDCl3) δ 178.67, 151.82, 149.00,147.82, 135.85, 130.34, 123.20, 121.37, 120.57, 113.20, 111.86, 111.38,77.24, 71.30, 55.89, 46.49, 44.23, 40.87, 38.18, 34.62, 34.35, 33.91, 12.99,12.44.
[0036] Example 3: Synthesis of compound A-3
[0037]
[0038] Weigh 200 mg of arctigenin and dissolve it in 5 mL of dichloromethane. Add 215 mg of 4-methylpiperazine-1-formyl chloride hydrochloride and 300 mg of potassium carbonate. Stir at room temperature, and the reaction is confirmed by TLC. Extract the reaction mixture with equal volumes of dichloromethane and water, repeating the extraction three times. Retain the organic phase, dry it with anhydrous sodium sulfate, and remove excess solvent by vacuum distillation. Purify the crude product by column chromatography to obtain the pure product. 1H NMR (400 MHz, CDCl3) δ 7.01 (d, J = 8.0 Hz, 1H), 6.84 – 6.75 (m, 2H), 6.69 (dd, J = 8.0, 2.0 Hz, 1H), 6.62 – 6.51 (m, 2H), 4.18 (dd, J = 9.1, 7.1 Hz, 1H), 3.96 – 3.88 (m, 1H), 3.87 (d, J = 9.4 Hz, 6H), 3.81 (s, 3H), 3.78 (s, 2H), 3.65 (s, 2H), 3.00 (d, J = 5.9 Hz, 2H), 2.75– 2.48 (m, 8H), 2.42 (s, 3H), 1.46 (s, 0H), 1.29 (s, 1H), 0.95 – 0.87 (m,1H). 13 C NMR (101 MHz, CDCl3) δ 178.63, 153.47, 151.65, 149.01, 147.84,139.35, 136.05, 130.32, 123.03, 121.42, 120.57, 113.24, 111.86, 111.38,77.24, 71.28, 55.92, 55.89, 54.75, 46.48, 46.19, 44.60, 43.98, 40.91, 38.17,36.50, 34.61.
[0039] Example 4: Synthesis of compound A-4
[0040]
[0041] 100 mg of arctigenin was dissolved in 3 mL of dichloromethane, and 145 mg of isocyanate chloride was added. 75 μL of triethylamine was added in an ice-water bath. After the reaction stabilized, the mixture was stirred at room temperature, and the reaction was monitored by TLC until complete. The pH was adjusted to 5-6 using 0.5 M ammonium chloride. The reaction mixture was extracted with equal volumes of dichloromethane and water, and the extraction was repeated three times. The organic phase was retained, dried over anhydrous sodium sulfate, and excess solvent was removed by vacuum distillation. The crude product was purified by column chromatography to obtain the pure product. 1H NMR (400 MHz, CDCl3)δ 8.88 (d, J = 5.5 Hz, 2H), 8.06 – 7.98 (m, 2H), 7.08 (d, J = 8.0 Hz, 1H), 6.85 – 6.78 (m, 2H), 6.75 (dd, J = 8.0, 1.9 Hz, 1H), 6.59 (dd, J = 8.1, 2.0Hz, 1H), 6.55 (d, J = 2.1 Hz, 1H), 4.22 (dd, J = 9.1, 7.2 Hz, 1H), 3.94 (dd,J = 9.1, 7.7 Hz, 1H), 3.88 (s, 3H), 3.86 (s, 3H), 3.78 (s, 3H), 3.03 (d, J =5.9 Hz, 2H), 2.71 (dd, J = 13.5, 6.4 Hz, 1H), 2.66 (dd, J = 8.7, 2.8 Hz, 1H), 2.59 (t, J = 7.7 Hz, 1H), 2.57 – 2.50 (m, 1H). 13 C NMR (101 MHz, CDCl3) δ178.50, 163.27, 151.10, 150.69, 149.06, 147.91, 138.35, 137.26, 136.71,130.25, 123.39, 122.46, 121.56, 120.58, 113.49, 111.85, 111.39, 77.24, 71.29,55.91, 55.89, 46.45, 41.04, 41.02, 38.16, 34.62.
[0042] Example 5: Synthesis of compound A-5
[0043]
[0044] 100 mg of arctigenin was dissolved in 3 mL of dichloromethane, and 142 mg of 6-chloronicotinyl chloride was added. 75 μL of triethylamine was added in an ice-water bath. After the reaction stabilized, the mixture was stirred at room temperature, and the reaction was monitored by TLC until completion. The pH was adjusted to 5-6 using 0.5 M ammonium chloride. The reaction mixture was extracted with equal volumes of dichloromethane and water, and the extraction was repeated three times. The organic phase was retained, dried over anhydrous sodium sulfate, and excess solvent was removed by vacuum distillation. The crude product was purified by column chromatography to obtain the pure product. 1H NMR (400 MHz, CDCl3)δ 9.22 – 9.15 (m, 1H), 8.40 (dd, J = 8.3, 2.4 Hz, 1H), 7.51 (dd, J = 8.3, 0.7Hz, 1H), 7.08 (d, J = 8.0 Hz, 1H), 6.86 – 6.77 (m, 2H), 6.75 (dd, J = 8.1,1.9 Hz, 1H), 6.59 (dd, J = 8.1, 2.0 Hz, 1H), 6.55 (d, J = 2.0 Hz, 1H), 4.22(dd, J = 9.1, 7.3 Hz, 1H), 3.94 (dd, J = 9.2, 7.7 Hz, 1H), 3.88 (s, 3H), 3.86(s, 3H), 3.78 (s, 3H), 3.03 (d, J = 5.9 Hz, 2H), 2.73 – 2.51 (m, 4H). 13 C NMR(101 MHz, CDCl3) δ 178.50, 162.60, 156.26, 151.77, 151.12, 149.06, 147.92,140.16, 138.22, 137.28, 130.25, 124.41, 124.38, 122.53, 121.56, 120.58,113.47, 111.86, 111.39, 77.24, 71.29, 55.91, 55.89, 46.45, 41.05, 38.16,34.62.
[0045] Example 6: Synthesis of compound A-6
[0046]
[0047] 300 mg of arctigenin was dissolved in 5 mL of dichloromethane. First, 310 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 150 mg of 4-dimethylaminopyridine were added and stirred at room temperature for 10 min. After the reaction stabilized, 140 mg of morpholino-4-ylacetic acid was added, and the reaction was continued at room temperature. The reaction was stopped by TLC. The reaction mixture was extracted with equal volumes of dichloromethane and water, and the extraction was repeated three times. The organic phase was retained, dried over anhydrous sodium sulfate, and excess solvent was removed by vacuum distillation. The crude product was purified by column chromatography to obtain the pure product. 1H NMR (600 MHz, CDCl3) δ 6.96 (d, J = 8.0 Hz, 1H), 6.80– 6.77 (m, 2H), 6.69 (dd, J = 8.0, 1.9 Hz, 1H), 6.57 (dd, J = 8.1, 2.0 Hz, 1H), 6.52 (d, J = 2.0 Hz, 1H), 4.19 (dd, J = 9.1, 7.4 Hz, 1H), 3.91 (dd, J =9.1, 7.9 Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 3.80 (t, J = 4.7 Hz, 4H), 3.77(s, 3H), 3.52(s, 2H), 2.99 (d, J = 6.0 Hz, 2H), 2.72 (t, J = 4.6 Hz, 4H), 2.68 (dd, J = 13.7, 6.5 Hz, 1H), 2.64 (dd, J = 8.7, 5.9 Hz, 1H), 2.62 – 2.58(m, 1H), 2.52 (p, J = 7.7 Hz, 1H). 13 C NMR (101 MHz, CDCl3) δ 178.54, 168.08,151.00, 149.03, 147.88, 138.29, 136.83, 130.25, 122.54, 121.46, 120.56,113.27, 111.84, 111.38, 77.24, 71.27, 66.81, 59.34, 55.90, 55.88, 55.81,53.45, 53.14, 46.42, 40.99, 38.12, 34.58.
[0048] Example 7: Synthesis of compound A-7
[0049]
[0050] Weigh 300 mg of arctigenin and dissolve it in 5 mL of dichloromethane. First, add 310 mg of 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride and 150 mg of 4-dimethylaminopyridine, and stir at room temperature for 10 min. After the reaction stabilizes, add 153 mg of 4-methyl-1-piperazinacetic acid and continue the reaction at room temperature. The reaction is complete when detected by TLC. Extract the reaction solution with equal volumes of dichloromethane and water, repeating the extraction three times. Retain the organic phase, dry it with anhydrous sodium sulfate, and remove excess solvent by vacuum distillation. The crude product is then purified by column chromatography to obtain the pure product.1 H NMR (600 MHz, CDCl3) δ 6.96 (d, J = 8.0 Hz, 1H), 6.81 – 6.75 (m, 2H), 6.68 (dd, J = 8.0, 2.0 Hz, 1H), 6.56 (dd, J = 8.1, 2.0Hz, 1H), 6.52 (d, 3.77 (d, J = 3.6 Hz, 3H), 3.52 (d, J = 3.6 Hz, 2H), 2.99 (dd, J = 6.0, 1.9Hz, 2H), 2.75 (s, 3H), 2.70 – 2.59 (m, 4H), 2.59 – 2.52 (m, 4H), 2.50 (d, J =7.9 Hz, 1H), 2.34 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 178.56, 168.32, 151.06,149.02, 147.86, 138.36, 136.74, 130.26, 122.59, 121.43, 120.55, 113.24,111.83, 111.38, 71.27, 55.88, 55.81, 54.83, 52.82, 46.42, 45.98, 40.98,38.13, 34.67, 34.60, 31.60, 25.29, 11.45.
[0051] Example 8: Synthesis of compound A-8
[0052]
[0053] 100 mg of arctigenin was dissolved in 3 mL of DMF, and 97 mg of trimethylacetyl chloride and 300 mg of potassium carbonate were added. The mixture was stirred at room temperature, and the reaction was monitored by TLC until completion. The reaction solution was extracted with equal volumes of ethyl acetate and water, and the extraction was repeated three times. The organic phase was retained, dried over anhydrous sodium sulfate, and excess solvent was removed by vacuum distillation. The crude product was purified by column chromatography to obtain the pure product. 1H NMR (400 MHz, CDCl3) δ 6.93 (d, J = 7.9 Hz, 1H), 6.80 – 6.74(m, 2H), 6.69 (dd, J = 8.0, 1.9 Hz, 1H), 6.55 (dd, J = 8.1, 2.1 Hz, 1H), 6.51(d, J = 2.0 Hz, 1H), 4.18 (dd, J = 9.1, 7.1 Hz, 1H), 3.91 (dd, J = 9.2, 7.4Hz, 1H), 3.87 (s, 3H), 3.85 (s, 3H), 3.76 (s, 3H), 3.06 – 2.94 (m, 2H), 2.70– 2.51 (m, 4H), 1.37 (s, 9H). 13 C NMR (101 MHz, CDCl3) δ 178.62, 176.74,151.34, 148.99, 147.83, 139.14, 136.31, 130.30, 122.60, 121.41, 120.52,113.25, 111.86, 111.37, 77.24, 71.31, 55.87, 55.86, 46.47, 40.94, 39.07,38.18, 34.70, 34.52, 27.22, 26.52.
[0054] Example 9: Synthesis of compound A-9
[0055]
[0056] 100 mg of arctigenin was dissolved in 3 mL of DMF, and 109 mg of 3,3-dimethylbutyryl chloride and 300 mg of potassium carbonate were added. The mixture was stirred at room temperature, and the reaction was monitored by TLC until completion. The reaction solution was extracted with equal volumes of ethyl acetate and water, and the extraction was repeated three times. The organic phase was retained, dried over anhydrous sodium sulfate, and excess solvent was removed by vacuum distillation. The crude product was purified by column chromatography to obtain the pure product. 1H NMR (400 MHz, CDCl3) δ 6.94 (d, J = 7.9 Hz, 1H), 6.81 –6.73 (m, 2H), 6.68 (dd, J = 8.0, 1.9 Hz, 1H), 6.55 (dd, J = 8.1, 2.0 Hz, 1H), 6.51 (d, J = 2.0 Hz, 1H), 4.19 (dd, J = 9.1, 7.2 Hz, 1H), 3.92 (dd, J = 9.1,7.5 Hz, 1H), 3.87 (s, 3H), 3.84 (s, 3H), 3.78 (s, 3H), 3.00 (d, J = 5.9 Hz, 2H), 2.65 (s, 4H), 2.47 (s, 2H), 1.16 (s, 9H). 13 C NMR (101 MHz, CDCl3) δ178.61, 170.22, 151.27, 149.01, 147.84, 138.70, 136.47, 130.28, 122.76,121.43, 120.54, 113.26, 111.83, 111.35, 77.24, 71.30, 55.89, 55.86, 55.68,47.61, 46.43, 41.14, 40.91, 38.14, 34.59, 31.04, 29.59.
[0057] Example 10: Synthesis of compound A-10
[0058]
[0059] 100 mg of arctigenin was dissolved in 3 mL of DMF, followed by the addition of 115 mg of iodomethane and 300 mg of potassium carbonate. The reaction was monitored by TLC until completion. The reaction mixture was extracted with equal volumes of ethyl acetate and water, and the extraction was repeated three times. The organic phase was retained, dried over anhydrous sodium sulfate, and excess solvent was removed by vacuum distillation. The crude product was purified by column chromatography to obtain a pure product. 1HNMR (400 MHz, CDCl3) δ 6.78 (t, J = 7.8 Hz, 2H), 6.72 – 6.66 (m, 2H), 6.57(dd, J = 8.2, 2.0 Hz, 1H), 6.51 (d, J = 2.0 Hz, 1H), 4.18 – 4.12 (m, 1H), 3.94 – 3.89 (m, 1H), 3.88 (d, J = 1.6 Hz, 6H), 3.85 (d, J = 5.0 Hz, 6H), 3.03– 2.91 (m, 2H), 2.71 – 2.47 (m, 4H). 13 C NMR (101 MHz, CDCl3) δ 178.75, 149.04,149.01, 147.93, 147.85, 130.44, 130.18, 121.35, 120.56, 112.30, 111.78,111.27, 111.03, 77.24, 71.27, 55.91, 55.87, 55.83, 46.59, 41.08, 38.20,34.50.
[0060] Example 11: Synthesis of compound A-11
[0061]
[0062] Weigh 200 mg of arctigenin and dissolve it in 5 mL of acetone. Add 192 mg of 4-pentenoyl chloride and 300 mg of potassium carbonate. Stir at room temperature, and the reaction is complete as detected by TLC. Extract the reaction solution with equal volumes of ethyl acetate and water. Repeat the extraction operation three times, retaining the organic phase. Dry the solution with anhydrous sodium sulfate and remove excess solvent by vacuum distillation. Purify the crude product by column chromatography to obtain the pure product. 1H NMR (400 MHz, CDCl3) δ 6.94 (d, J = 7.9 Hz, 1H), 6.82 – 6.75(m, 2H), 6.68 (dd, J = 8.0, 1.9 Hz, 1H), 6.56 (dd, J = 8.1, 2.0 Hz, 1H), 6.52(d, J = 2.0 Hz, 1H), 5.93 (ddt, J = 16.8, 10.3, 6.4 Hz, 1H), 5.19 – 5.06 (m,2H), 4.19 (dd, J = 9.1, 7.2 Hz, 1H), 3.92 (dd, J = 9.1, 7.5 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.78 (s, 3H), 3.03 – 2.95 (m, 2H), 2.73 – 2.47 (m, 8H). 13 CNMR (101 MHz, CDCl3) δ 178.59, 171.13, 151.20, 149.01, 147.85, 138.66,136.57, 136.44, 130.27, 122.66, 121.43, 120.54, 115.74, 113.27, 111.82,111.35, 71.30, 55.89, 55.86, 55.81, 46.43, 40.95, 38.14, 34.61, 33.23, 28.90.
[0063] Example 12: Synthesis of compound A-12
[0064]
[0065] 100 mg of arctigenin was dissolved in 3 mL of DMF, along with 70 mg of acetyl chloride and 300 mg of potassium carbonate. The mixture was stirred at room temperature, and the reaction was monitored by TLC until completion. The reaction solution was extracted with equal volumes of ethyl acetate and water, and the extraction was repeated three times. The organic phase was retained, dried over anhydrous sodium sulfate, and excess solvent was removed by vacuum distillation. The crude product was purified by column chromatography to obtain the pure product. 1H NMR (400 MHz, CDCl3) δ 6.96 (d, J = 8.0 Hz, 1H), 6.83 – 6.76 (m, 2H), 6.69 (dd, J = 8.0, 1.9 Hz, 1H), 6.56 (dd, J = 8.1, 2.1 Hz, 1H), 6.52 (d, J =2.0 Hz, 1H), 4.20 (dd, J = 9.1, 7.2 Hz, 1H), 3.92 (dd, J = 9.1, 7.6 Hz, 1H), 3.88 (s, 3H), 3.85 (s, 3H), 3.79 (s, 3H), 3.00 (d, J = 5.9 Hz, 2H), 2.71 –2.49 (m, 4H), 2.33 (s, 3H). 13 C NMR (101 MHz, CDCl3) δ 178.57, 169.03, 151.19,149.03, 147.87, 138.64, 136.63, 130.26, 122.66, 121.44, 120.56, 113.30,111.82, 111.36, 71.29, 55.90, 55.86, 55.84, 46.42, 40.99, 38.14, 34.59,20.69.
[0066] Example 13: Synthesis of compound A-13
[0067]
[0068] 100 mg of arctigenin was dissolved in 3 mL of acetone, followed by the addition of 85 mg of cyclopropionyl chloride and 300 mg of potassium carbonate. The mixture was stirred at room temperature, and the reaction was monitored by TLC until completion. The reaction solution was extracted with equal volumes of ethyl acetate and water, and the extraction was repeated three times. The organic phase was retained, dried over anhydrous sodium sulfate, and excess solvent was removed by vacuum distillation. The crude product was purified by column chromatography to obtain the pure product. 1H NMR (400 MHz, CDCl3) δ 6.97 (d, J = 8.0 Hz, 1H), 6.81 – 6.73 (m,2H), 6.68 (dd, J = 8.0, 2.0 Hz, 1H), 6.55 (dd, J = 8.1, 2.1 Hz, 1H), 6.51 (d,J = 2.1 Hz, 1H), 4.19 (dd, J = 9.1, 7.2 Hz, 1H), 3.91 (dd, J = 9.1, 7.5 Hz,1H), 3.87 (s, 3H), 3.84 (s, 3H), 3.79 (s, 3H), 3.04 – 2.93 (m, 2H), 2.68 –2.46 (m, 4H), 1.89 (tt, J = 8.0, 4.6 Hz, 1H), 1.18 (dt, J = 4.7, 3.3 Hz, 2H), 1.04 (dt, J = 7.3, 3.2 Hz, 2H). 13 C NMR (101 MHz, CDCl3) δ 178.60, 173.05,151.34, 149.00, 147.83, 138.70, 136.45, 130.27, 122.78, 121.41, 120.54,113.28, 111.83, 111.36, 77.24, 71.30, 55.89, 55.86, 46.43, 40.95, 38.16,34.63, 12.79, 10.21, 9.24.
[0069] Example 14: Synthesis of compound A-14
[0070]
[0071] 100 mg of arctigenin was dissolved in 3 mL of DMF, and 181 mg of hexanoyl chloride was added. The reaction was carried out at room temperature for 4 hours, and the reaction was stopped by TLC. The reaction solution was extracted with equal amounts of ethyl acetate and water, and the extraction was repeated three times. The organic phase was retained, dried over anhydrous sodium sulfate, and excess solvent was removed by vacuum distillation. The crude product was purified by column chromatography to obtain the pure product. 1H NMR(600 MHz, CDCl3) δ 6.95 (d, J = 8.0 Hz, 1H), 6.80 – 6.75 (m, 2H), 6.68 (dd, J= 8.0, 1.9 Hz, 1H), 6.55 (dd, J = 8.1, 2.0 Hz, 1H), 6.52 (d, J = 2.0 Hz, 1H), 4.19 (dd, J = 9.1, 7.4 Hz, 1H), 3.92 (dd, J = 9.1, 7.7 Hz, 1H), 3.88 (s, 3H), 3.84 (s, 3H), 3.78 (s, 3H), 3.04 – 2.95 (m, 2H), 2.68 (dd, J = 13.7, 6.5 Hz,1H), 2.65 – 2.62 (m, 1H), 2.62 – 2.59 (m, 1H), 2.59 – 2.56 (m, 2H), 2.52 (td,J = 7.9, 6.3 Hz, 1H), 1.77 (p, J = 7.4 Hz, 2H), 1.45 – 1.36 (m, 4H), 0.95 (t,J = 7.1 Hz, 3H). 13 C NMR (101 MHz, CDCl3) δ 178.60, 171.91, 151.24, 149.01,147.85, 138.75, 136.48, 130.28, 122.69, 121.43, 120.54, 113.26, 111.84,111.37, 71.30, 55.89, 55.86, 55.81, 46.44, 40.96, 38.15, 34.63, 33.99, 31.22,24.72, 22.35, 13.98.
[0072] Example 15: PP2A activation activity assay
[0073] HEK293T cells were seeded in 6-well plates and cultured to 70-80% confluence. Different treatments were then administered: control group (DMSO), arctigenin (10 μM), and a series of derivatives (10 μM), for 2 hours. After cell lysis, protein phosphokinase A activity was detected using a PP2A activity kit (Promega, V2460). Results are shown below. Figure 1 As shown, all compounds can activate PP2A at a concentration of 10 μM, with A-9 exhibiting the strongest activity (2.79 times), while A-3 (2.08 times) and ATG (2.23 times) have comparable activities.
[0074] Example 16: CCK8 cell viability assay
[0075] MPC-5, HEK293, and HEK293T cells were induced at a rate of 2 × 10⁻⁶. 4 Cells were seeded in 96-well plates and treated with a series of 10 μM derivatives for 24 hours. Then, 10 μL of CCK8 reagent was added, and the cells were incubated at 37°C for 2 hours. The absorbance at 450 nm was measured. Cell viability (%) = (OD of experimental group / OD of NG group) × 100%. Figure 2 A heatmap showing the survival rates of arctigenin (ATG) and its 14 derivatives (A-1 to A-14) at a concentration of 10 μM in MPC5, HEK293T, and HEK293 cells after 24 hours of treatment. Red indicates low survival rate (high cytotoxicity), and blue indicates high survival rate (low cytotoxicity). The results show that A-3 exhibited high survival rates in all three cell types (blue), while A-1 and A-10 also showed good cell safety with high survival rates. ATG, however, showed low survival rates in HEK293T cells (red), indicating that these derivatives (especially A-3) have superior cell safety.
[0076] Example 17: Comparison of metabolic stability of arctigenin derivatives
[0077] The metabolic stability of 13 arctigenin derivatives was evaluated using liver S9. An in vitro metabolic system (total volume 500 μL) containing liver S9 (0.5 mg / mL), the compound (2 μM), and NADPH (1 mM) was established and incubated at 37 °C. 100 μL samples were taken at 0, 5, 15, 30, 45, and 60 min, and the reaction was terminated by adding ice-cold acetonitrile containing an internal standard. After centrifugation, the supernatant was analyzed by HPLC, and the chemical half-life was calculated. The results are shown in the table below.
[0078] Compound <![CDATA[t 1 / 2(min) ]]> Compound <![CDATA[t 1 / 2(min) ]]> ATG 5.94 A-8 10.02 A-1 52.16 A-9 8.87 A-2 194.43 A-10 20.34 A-3 208.34 A-11 4.83 A-4 10.16 A-12 6.46 A-5 7.81 A-13 6.95 A-6 14.33 A-14 8.59 A-7 3.35
[0079] Example 18: Comparison of equilibrium solubility of arctigenin derivatives
[0080] The equilibrium solubility of the compounds in pure water (37℃) was determined using the shake-flask method. First, each compound was added to pure water to prepare a 5 mM solution, and its solubility was observed. The results showed that among the 14 derivatives, only A-1, A-3, A-6, and A-7 were completely soluble at the 5 mM concentration; the remaining derivatives did not reach this solubility threshold. Further equilibrium solubility determination was performed on these four soluble derivatives: an excess of the compound was added to 1 mL of pure water, shaken at 37℃ for 24 hours, filtered through a 0.22 μm filter membrane, and the concentration of the filtrate was determined by HPLC. The results showed that the solubility of A-1 was 7.69 μg / μL, A-3 was 136.3 μg / μL, A-6 was 2.6 μg / μL, and A-7 was 61.51 μg / μL. The solubility of A-3 was about 390 times higher than that of arctigenin (0.349 μg / μL), indicating that the introduction of N-methylpiperazinformyl group at C4 position significantly improved the water solubility of the compound.
[0081] Example 19: Determination of the activation activity of representative compound PP2A
[0082] HEK293T cells were seeded in 6-well plates and cultured to 70-80% confluence. Different treatments were then administered: control group (DMSO), A-3 (1, 3.3, 10 μM), for 2 hours. After cell lysis, protein phosphokinase A activity was detected using a PP2A activity kit (Promega, V2460). Figure 3 The activation effect of A-3 on PP2A activity in HEK293T cells at concentrations of 1, 3.3, and 10 μM was concentration-dependent.
[0083] Example 20: Protective effect of representative compounds against high glucose-induced podocyte injury
[0084] MPC5 mouse podocytes were injected at a dose of 2 × 10⁻⁶. 4 Cells were seeded in 96-well plates and, after complete differentiation, were synchronized for 12 hours using serum-free medium. Cells were divided into the following groups: Normal control group (NG): containing 5 mM glucose + 35 mM mannitol (isotonic control); High glucose model group (HG): containing 40 mM glucose, HG + A-3 (1 μM), HG + A-3 (3.3 μM), HG + A-3 (10 μM), and HG + ATG (10 μM) (positive control). After 24 hours of treatment, 10 μL of CCK8 reagent was added to each well, and the cells were incubated at 37°C for 2 hours. The absorbance at 450 nm was measured using a microplate reader. Cell viability (%) = (OD value of experimental group / OD value of normal control group) × 100%. Results are as follows: Figure 4The results showed that high glucose induced a significant decrease in the viability of MPC5 cells, and cell viability was restored in a concentration-dependent manner after intervention with A-3 (1, 3.3, 10 μM).
[0085] Example 21: Effect of representative compounds on high glucose-induced podocyte cell adhesion.
[0086] Differentiated MPC5 cells were fed at a rate of 2×10 5 Cells were seeded in 6-well plates and treated with either normal glucose (5 mM + 35 mM mannitol) or high glucose (40 mM), with A-3 (1, 3.3, 10 μM) or ATG (10 μM) added simultaneously. After 24 hours of culture, cells were digested with trypsin, counted, and seeded at 5 x 10⁻⁶ cells / well. 4 Cells were seeded in 24-well plates pre-coated with fibronectin (10 μg / mL) and incubated at 37°C for 1 hour to allow adhesion. Unadhered cells were gently washed away with PBS, fixed with 4% paraformaldehyde, stained with 0.1% crystal violet, excess dye was washed away, and the cells were dissolved in 30% acetic acid. The absorbance at 570 nm was measured. Adhesion rate (%) = (OD value of adhered cells / OD value of total seeded cells) × 100%. Results are as follows. Figure 4 The results showed that high glucose induced a significant decrease in the adhesion ability of MPC5 cells, while A-3 (1, 3.3, 10 μM) intervention enhanced cell adhesion in a concentration-dependent manner. The results are as follows... Figure 4 As shown.
[0087] The preparation method of the general formula compound of the present invention has been described above with reference to specific embodiments, but these specific methods do not constitute any limitation on the present invention. The compounds of the present invention can also be conveniently prepared by optionally combining various synthetic methods described in this specification or known in the art, and such combinations can be easily performed by those skilled in the art.
Claims
1. Arctinoside derivatives, with the following general formula: , in, P is selected from C1-C8 aliphatic acyl, N-substituted carbamoyl, aromatic heterocyclic carbamoyl, saturated heterocyclic alkyl acyl or methyl.
2. The arctigenin derivative according to claim 1, characterized in that: The P is selected from pivaloyl, 3,3-dimethylbutyryl, acetyl, n-hexanoyl, cyclopropylformyl, 4-pentenyl, N,N-diethylcarbamoyl, N-ethyl-N-methylcarbamoyl, N-methylpiperazincarbamoyl, pyridine-4-formyl, 2-chloro-pyridine-4-formyl, morpholinylacetyl, 4-methylpiperidinylacetyl, or methyl.
3. The arctigenin derivative according to claim 1, characterized in that: The P is selected from N-methylpiperazinyl.
4. The method for preparing the arctigenin derivative as described in claim 1, characterized in that, The process includes the following steps: dissolving arctigenin in an organic solvent, adding the corresponding acyl chloride or alkyl halide, and reacting in the presence of a base; or adding the corresponding carboxylic acid, and reacting in the presence of EDCI and DMAP, followed by separation and purification to obtain arctigenin derivatives.
5. The method for preparing the arctigenin derivative according to claim 4, characterized in that: The organic solvent is selected from DMSO, DMF, and dichloromethane.
6. The method for preparing the arctigenin derivative according to claim 4, characterized in that: The alkali is selected from triethylamine and potassium carbonate.
7. A pharmaceutical composition for treating diabetic nephropathy, wherein the active ingredient comprises the arctigenin derivative of any one of claims 1-3 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.
8. The use of the arctigenin derivative as described in any one of claims 1-3 in the preparation of a drug for treating diabetic kidney disease.
9. The use of the arctigenin derivative according to claim 8 in the preparation of a drug for treating diabetic nephropathy, wherein the nephropathy is selected from MPC-5, HEK293, and HEK293T cell damage.
